Notably, in keeping with previous reports17,20, we found that CDK6 silencing was the top scoring genetic event for enhancing efficacy of CDK4/6i, and RB1 depletion was the top hit for promoting resistance in breast cancer cells to CDK4/6i (Fig. 1a). Here, RB1 is linked to breast carcinoma.